Effect of magnesium hydroxide on the absorption of tolfenamic and mefenamic acids. 1988

P J Neuvonen, and K T Kivistö
Department of Clinical Pharmacology, University of Helsinki, Finland.

The effect of various antacids on the absorption of tolfenamic and mefenamic acids has been investigated in three separate crossover studies, each consisting of four phases. Single doses of magnesium hydroxide (85 mg, 425 mg and 1700 mg) or of water (150 ml) were given by mouth to 6 healthy volunteers immediately after tolfenamic acid 400 mg (Study 1), and, using an identical study design, after mefenamic acid 500 mg (Study 3). In Study 2 sodium bicarbonate 1 g, aluminium hydroxide 1 g, an antacid preparation containing both aluminium and magnesium hydroxides, or water alone were ingested with tolfenamic acid 400 mg. Plasma concentrations of tolfenamic and mefenamic acids and their cumulative excretion in urine were determined up to 24 h. Magnesium hydroxide greatly accelerated, in a dose-dependent manner the absorption of both tolfenamic and mefenamic acids. The peak times in plasma were shortened by about 1 h by 425 mg and 1700 mg magnesium hydroxide, and the peak plasma concentrations of both fenamates were elevated up to 3-fold. The area under the plasma concentration-time curve between 0 and 1 h of tolfenamic acid was increased up to 7-fold and that of mefenamic acid up to 3-fold. The total bioavailability of tolfenamic and mefenamic acids was only slightly increased. Aluminium hydroxide alone and in combination with magnesium hydroxide significantly retarded the absorption and lowered the peak plasma concentration of tolfenamic acid. Sodium bicarbonate had no significant effect on its absorption. The interaction with magnesium hydroxide leads to higher and earlier peak plasma concentrations of the fenamates.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007408 Intestinal Absorption Uptake of substances through the lining of the INTESTINES. Absorption, Intestinal
D008274 Magnesium A metallic element that has the atomic symbol Mg, atomic number 12, and atomic weight 24.31. It is important for the activity of many enzymes, especially those involved in OXIDATIVE PHOSPHORYLATION.
D008276 Magnesium Hydroxide An inorganic compound that occurs in nature as the mineral brucite. It acts as an antacid with cathartic effects. Brucite,Magnesium Hydrate,Magnesium Hydroxide (Mg(OH)4),Hydrate, Magnesium,Hydroxide, Magnesium
D008528 Mefenamic Acid A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase. Apo-Mefenamic,Contraflam,Coslan,Dysman,Mefac,Mefacit,Mefenaminic Acid,Mefic,Nu-Mefenamic,PMS-Mefenamic Acid,Parkemed,Pinalgesic,Ponalar,Ponalgic,Ponmel,Ponstan,Ponstan Forte,Ponstel,Ponsyl,Pontal,Acid, Mefenamic,Apo Mefenamic,Nu Mefenamic,PMS Mefenamic Acid
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000863 Antacids Substances that counteract or neutralize acidity of the GASTROINTESTINAL TRACT. Alkalinizing Agent,Antacid,Alkalinizing Agents,Agent, Alkalinizing,Agents, Alkalinizing
D000894 Anti-Inflammatory Agents, Non-Steroidal Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Analgesics, Anti-Inflammatory,Aspirin-Like Agent,Aspirin-Like Agents,NSAID,Non-Steroidal Anti-Inflammatory Agent,Non-Steroidal Anti-Inflammatory Agents,Nonsteroidal Anti-Inflammatory Agent,Anti Inflammatory Agents, Nonsteroidal,Antiinflammatory Agents, Non Steroidal,Antiinflammatory Agents, Nonsteroidal,NSAIDs,Nonsteroidal Anti-Inflammatory Agents,Agent, Aspirin-Like,Agent, Non-Steroidal Anti-Inflammatory,Agent, Nonsteroidal Anti-Inflammatory,Anti-Inflammatory Agent, Non-Steroidal,Anti-Inflammatory Agent, Nonsteroidal,Anti-Inflammatory Analgesics,Aspirin Like Agent,Aspirin Like Agents,Non Steroidal Anti Inflammatory Agent,Non Steroidal Anti Inflammatory Agents,Nonsteroidal Anti Inflammatory Agent,Nonsteroidal Anti Inflammatory Agents,Nonsteroidal Antiinflammatory Agents
D062367 ortho-Aminobenzoates Benzoic acids, salts, or esters that contain an amino group attached to carbon number 2 or 6 of the benzene ring structure. 2-Aminobenzoates,6-Aminobenzoates,Anthranilates,Anthranilic Acids,o-Aminobenzoates,o-Aminobenzoic Acids,ortho-Aminobenzoic Acids,6 Aminobenzoates,Acids, Anthranilic,Acids, o-Aminobenzoic,Acids, ortho-Aminobenzoic,o Aminobenzoates,o Aminobenzoic Acids,ortho Aminobenzoates,ortho Aminobenzoic Acids

Related Publications

P J Neuvonen, and K T Kivistö
November 1999, Annals of emergency medicine,
P J Neuvonen, and K T Kivistö
January 1974, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
P J Neuvonen, and K T Kivistö
March 2016, Pulmonary circulation,
P J Neuvonen, and K T Kivistö
March 1991, British journal of clinical pharmacology,
P J Neuvonen, and K T Kivistö
October 1982, International journal of clinical pharmacology, therapy, and toxicology,
P J Neuvonen, and K T Kivistö
July 1973, Schweizerische medizinische Wochenschrift,
P J Neuvonen, and K T Kivistö
February 1976, Clinical pharmacology and therapeutics,
P J Neuvonen, and K T Kivistö
May 1973, Oral surgery, oral medicine, and oral pathology,
P J Neuvonen, and K T Kivistö
October 1993, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!